Bad News For Remedesivir In COVID-19 Battle
In the large COVID-19 clinical trial sponsored by World Health Organization (WHO), Remedesivir was found not to decrease the mortality rate of hospitalized patients and not to even shorten the recovery time of those who do survive. This recent finding contradicts the earlier announced smaller studies which found that Remdesivir, an antiviral drug, decreased hospitalization period for COVID-19 patients more than those who received a placebo. Those earlier studies led the FDA to grant emergency use authorization for the drug. The WHO-Trial was conducted from March 22 to Oct. 4 and involved 11,330 patients from 405 hospitals in 30 countries. Patients were given Remdesivir and three other drugs singly or in combination. The U.S. pharmaceutical company Gilead Sciences, the manufacturer of Remdesivir, issued a statement defending the drug, mentioning that controlled studies published in peer-reviewed journals validated its benefits.
Source: 1. Medscape. Remdesivir Does Not Reduce COVID-19 Mortality, Study Says. https://www.medscape.com/viewarticle/939289. Published 16 October 2020. Accessed 18 October 2020.